Zimmer Biomet Holdings ZBH

$91.62 +0.58 (0.64%)

Valuation

Market cap
17,364,788,000
Revenue TTM
$8,231,500,000
Net income TTM
$705,200,000
PE ratio
10.58
Forward PE
10.51
Profit margin
8.57%
Debt to equity
0.59

Trading

Volume
1,628,300
Avg volume
2,136,052
Day's range
$90.09 – $91.84
Shares out
190,738,000
Stochastic %K
28%
Beta
0.47
Analysts
Sell
Price target
$105.42

Price

Company profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in...

Show more

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Industry
Medical Devices
Sector
Healthcare
Phone
574 373 3333
Website
https://www.zimmerbiomet.com
Address
345 East Main Street, Warsaw, United States

Latest news

Stocktwits

BioTechHealthX Sep 26, 1:29 PM
$ZBH Zimmer Biomet already sells the ROSA surgical robotics platform. Now it is preparing for a Monogram robot launch expected in 2027. Here is what investors should watch next. https://biotechhealthx.com/biotech-news/zimmer-biomet-zbh-has-a-new-robot-coming-can-it-deliver/
0 replies
BioTechHealthX Sep 25, 7:28 AM
$ISRG $PRCT $MDT $SYK $ZBH Medical robots do far more than assist surgeons. This countdown covers surgical robotics, pharmacy automation and robotic radiotherapy stocks for 2026. https://biotechhealthx.com/biotech-news/top-5-medical-robotics-stocks-to-buy-today/
0 replies
Boston7452 Sep 16, 10:18 PM
$SINT $ZBH $SOLV Google estimate the revenue increase from a three way merger between these companies. The number reflect 25% increase in margins justified by Sintx Si3N4 ability to reduce HAI. Not sure how it estimated Sintx product sales but in a 360 Bioshield GPO with “Si3N4 Inside” it’s plausible.
3 replies
Inphatec Sep 15, 5:45 PM 0 replies
Boston7452 Sep 8, 6:23 PM
$SINT $ZBH $SOLV $MMM $TMO Example of a 360 degree Bioshield with "Sintx Inside"
0 replies
Naguara Sep 8, 6:15 PM
$ZBH So striker says their ortho business is Down yet ZB who increased their outlook gets drop today as well. Lol. F WS full of crooks.
0 replies
Boston7452 Aug 13, 6:07 PM
$SINT $SOLV $ZBH That market capture is 2 years or so. It should grow rapidly after that as no product suite could compete against IP that is antipathogenic, bioactive encouraging bone and tissue healing, reduces metallosis, Hospital HAI, and improves imagining in additon to the base products already established.
0 replies
IN0V8 Aug 10, 6:47 PM
$ZBH Canaccord Genuity raises PT to $100 from $83
0 replies